KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Inventory (2016 - 2025)

Vertex Pharmaceuticals has reported Change in Inventory over the past 15 years, most recently at $77.4 million for Q4 2025.

  • Quarterly results put Change in Inventory at $77.4 million for Q4 2025, down 47.53% from a year ago — trailing twelve months through Dec 2025 was $524.2 million (up 1.33% YoY), and the annual figure for FY2025 was $524.2 million, up 1.33%.
  • Change in Inventory for Q4 2025 was $77.4 million at Vertex Pharmaceuticals, down from $131.1 million in the prior quarter.
  • Over the last five years, Change in Inventory for VRTX hit a ceiling of $182.5 million in Q3 2024 and a floor of -$2.0 million in Q1 2022.
  • Median Change in Inventory over the past 5 years was $77.9 million (2022), compared with a mean of $79.7 million.
  • Biggest five-year swings in Change in Inventory: plummeted 108.77% in 2022 and later skyrocketed 4230.0% in 2023.
  • Vertex Pharmaceuticals' Change in Inventory stood at $27.0 million in 2021, then skyrocketed by 190.0% to $78.3 million in 2022, then decreased by 10.6% to $70.0 million in 2023, then skyrocketed by 110.71% to $147.5 million in 2024, then tumbled by 47.53% to $77.4 million in 2025.
  • The last three reported values for Change in Inventory were $77.4 million (Q4 2025), $131.1 million (Q3 2025), and $148.6 million (Q2 2025) per Business Quant data.